Melika Moradi

Mrs. Melika Moradi


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2025 in Antibiotics
Verified
Journal Article
Open access
PDF file
MMMelika Moradi
Melika Moradi
EMEffat Abbasi Montazeri
Effat Abbasi Montazeri
SASirous Rafiei Asl
Sirous Rafiei Asl
Ali PormohammadAli Pormohammad
Ali Pormohammad
ZFZahra Farshadzadeh
Zahra Farshadzadeh
Raymond TurnerRaymond Turner
Raymond Turner
Background/Objectives: Biofilm-embedded bacteria, such as Pseudomonas aeruginosa (P. aeruginosa), are highly resistant to antibiotics, making their treatment challenging. Plant-based natural compounds (PBCs) and metal(loid)-based antimicrobials (MBAs) are promising alternatives. This study evaluated the minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC), and synergistic effects of zinc sulfate (ZnSO4), carvacrol (CV), and antibiotics (ciprofloxacin [CIP], tobramycin [TOB], and azithromycin [AZM]) against P. aeruginosa PAO1. Methods: The MIC and MBC of ZnSO4, CV, and antibiotics were determined using a 96-well plate method. Cytotoxicity was assessed via MTT assay. Fractional inhibitory concentration (FIC), fractional bactericidal concentration (FBC), minimal biofilm inhibition concentration (MBIC), and minimum biofilm eradication concentration (MBEC) indices were calculated for each combination of agents. Checkerboard assays identified interactions, and the effectiveness of combinations was further evaluated in a mouse chronic lung infection model with treatments delivered intratracheally, intraperitoneally, and orally. Results: TOB had the lowest MIC and MBC values, proving most effective against P. aeruginosa PAO1. Strong synergy was observed with CV + ZnSO4 (CV + Zn) combined with CIP, CV with CIP, and CV + Zn with TOB, as indicated by low FIC indices. CV + Zn with TOB and CV with TOB had low FBC indices, while CV + Zn with AZM showed antagonism. In vivo, intratracheal TOB + CV + Zn reduced lung inflammation and tissue involvement, yielding the best histopathological outcomes. The MIC of CIP and TOB was reduced 5-fold and 4-fold, respectively, when combined with CV + Zn. Conclusions: CV + Zn demonstrated strong synergistic effects with antibiotics and effectively managed P. aeruginosa lung infections in mice. These findings highlight its potential as an innovative therapy for biofilm-associated infections.

4 June 2024 in Microbiology Spectrum
Verified
Journal Article
Open access
Ali PormohammadAli Pormohammad
Ali Pormohammad
MMMelika Moradi
Melika Moradi
JHJosefien W. Hommes
Josefien W. Hommes
EPEugènia Pujol
Eugènia Pujol
LNLieve Naesens
Lieve Naesens
Raymond TurnerRaymond Turner
Raymond Turner
Novel antimicrobial agents are needed to combat antimicrobial resistance. This study tested novel pentafluorosulfanyl-containing triclocarban analogs for their potential antibacterial efficacy. Standard procedures were used to produce pentafluorosulfanyl-containing triclocarban analogs. Twenty new compounds were tested against seven Gram-positive and Gram-negative indicator strains as well as 10 clinical isolates for their antibacterial and antibiofilm activity. Mechanistic investigations focused on damage to cell membrane, oxidizing reduced thiols, iron-sulfur clusters, and oxidative stress to explain the compounds’ activity. Safety profiles were assessed using cytotoxicity experiments in eukaryotic cell lines. Following screening, selected components had significantly better antibacterial and antibiofilm activity against Gram-positive bacteria in lower concentrations in comparison to ciprofloxacin and gentamycin. For instance, one compound had a minimum inhibitory concentration of <0.0003 mM, but ciprofloxacin had 0.08 mM. Mechanistic studies show that these novel compounds do not affect reduced thiol content, iron-sulfur clusters, or hydrogen peroxide pathways. Their impact comes from Gram-positive bacterial cell membrane damage. Tests on cell culture toxicity and host component safety showed promise. Novel diarylurea compounds show promise as Gram-positive antimicrobials. These compounds offer prospects for study and optimization. IMPORTANCE: The rise of antibiotic resistance among bacterial pathogens poses a significant threat to global health, underscoring the urgent need for novel antimicrobial agents. This study presents research on a promising class of novel compounds with potent antibacterial properties against Gram-positive bacteria, notably Staphylococcus aureus and MRSA . What sets these novel analogs apart is their superior efficacy at substantially lower concentrations compared with commonly used antibiotics like ciprofloxacin and gentamycin. Importantly, these compounds act by disrupting the bacterial cell membrane, offering a unique mechanism that could potentially circumvent existing resistance mechanisms. Preliminary safety assessments also highlight their potential for therapeutic use. This study not only opens new avenues for combating antibiotic-resistant infections but also underscores the importance of innovative chemical approaches in addressing the global antimicrobial resistance crisis.

23 April 2026 in International Wound Journal
Verified
Journal Article
Open access
PDF file
MMMelika Moradi
Melika Moradi
APAli Pormohammad
Ali Pormohammad
CLCharline Luong
Charline Luong
Raymond TurnerRaymond Turner
Raymond Turner
Antimicrobial resistance ( AMR ) and biofilm formation significantly hinder chronic wound management, necessitating safer and more effective therapeutic options. This study evaluates the antimicrobial, antibiofilm, cytocompatibility and anti‐inflammatory properties of a novel antimicrobial hydrogel Formulation (#1) compared with commercially available wound hydrogel and cream Formulations (#2–5). Antimicrobial activity was assessed using minimum inhibitory concentration ( MIC ) and minimum bactericidal concentration ( MBC ) assays against Staphylococcus aureus , Pseudomonas aeruginosa , Candida albicans , and mixed‐species cultures. Biofilm‐related efficacy was evaluated via crystal violet ( CV ) staining and minimum biofilm inhibitory concentration ( MBIC ) assays. Cytotoxicity was examined using ISO ‐compliant MTT and confluency assays on L929 fibroblasts. In vivo anti‐inflammatory effects were assessed using intra‐cutaneous injection in New Zealand White rabbits with histological evaluation per ISO 10993‐23. Formulation 1 showed the lowest MIC and MBC values across all pathogens, including polymicrobial cultures, indicating strong broad‐spectrum efficacy. In biofilm assays, it reduced biofilm biomass by 50%–60% within 10 min and prevented new formation at lower MBIC values than Formulation 2, especially in mixed‐species models. Cytotoxicity testing confirmed Formulation 1 maintained ≥ 81% cell viability across all concentrations, outperforming other products and meeting ISO and USP safety thresholds. In vivo, both Formulation 1 and 2 induced minimal inflammation, with Formulation 1 showing slightly milder tissue responses. Formulation 1 demonstrated strong antimicrobial efficacy, reliable biofilm control, and favourable cytocompatibility compared with the comparator formulations tested in this study. These findings support further evaluation of this formulation for chronic wounds complicated by biofilms and antimicrobial resistance.

5 January 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
Ali PormohammadAli Pormohammad
Ali Pormohammad
MMMelika Moradi
Melika Moradi
JHJosefien W. Hommes
Josefien W. Hommes
EBEugènia Pujol Bech
Eugènia Pujol Bech
LNLieve Naesens
Lieve Naesens
Raymond TurnerRaymond Turner
Raymond Turner
The antibacterial and antibiofilm efficacy of our novel pentafluorosulfanyl-containing triclocarban analogs was explored against seven different Gram-positive and Gram-negative indicator strains. After initial screening, they had bactericidal and bacteriostatic activity against Gram-positive bacteria, especially Staphylococcus aureus and MRSA (methicillin–resistant staphylococcus aureus) in a very low concentration. Our results were compared with the most common antibiotic being used (Ciprofloxacin and Gentamycin); the novel components had significantly better antibacterial and antibiofilm activity in lower concentrations in comparison to the antibiotics. For instance, EBP- 59 minimum inhibitory concentration was < 0.0003 mM, while ciprofloxacin 0.08 mM. Further antibacterial activity of novel components was surveyed against 10 clinical antibiotic resistance MRSA isolates. Again, novel components had significantly better antibacterial and antibiofilm activity in comparison with antibiotics. Mechanistic studies have revealed that none of these novel compounds exhibit any effect on the reduced thiol, disrupting iron sulfur clusters, or hydrogen peroxide pathways. Instead, their impact is attributed to the disruption of the Gram-positive bacterial cell membrane. Toxicity and safety testing on tissue cell culture showed promising results for the safety of components to the host.

14 October 2021 in Ultrasound in Obstetrics & Gynecology
Verified
Journal Article
Open access
PDF file
MBM. Barati
M. Barati
SAS. Aberoumand
S. Aberoumand
MAM. Aberoumand
M. Aberoumand
MNM. Norbehahani
M. Norbehahani
FBF. Baesi
F. Baesi
MMMelika Moradi
Melika Moradi
Click on the article title to read more.